Niranib-100mg-Niraparib-Zejula is a medicine that helps maintain the response of specific types of the ovarian, fallopian tube, and peritoneal cancer in patients who have already responded or partially responded to other chemotherapy medications. It belongs to the PARP inhibitor class and functions by eliminating cancer cells. 
Niranib-100mg-Niraparib-Zejula is used for: Indication
- For Recurrent Ovarian Cancer: Niraparib 100mg maintains treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. patients have to start treatment with Niraparib 8 weeks after the platinum-containing regimen. Niraparib should be continued until the disease progresses or has unacceptable toxicity.
- For advanced ovarian cancer: Niraparib 100mg is the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. In case of advanced ovarian cancer, Niraparib should be used no later than 12 weeks after the platinum-containing regimen. 
Dosage and modification of Niranib-100mg-Niraparib-Zejula:
- 300mg starting dose:
- First dose reduction: 200 mg/day
- Second dose reduction: 100 mg/day
- Discontinue if further dose reduction <100 mg/day required
200 mg starting dose
- First dose reduction: 100 mg/day
- Discontinue if further dose reduction <100 mg/day is required 
Possible Side effect of Using Niraparib:
- vomiting 
Administration and storage of Niranib-100mg-Niraparib-Zejula:
Niranib-100mg-Niraparib-Zejula is an orally administrated medication that comes as a capsule. patients may take it with or without food. Take the medication at the same time each day. Swallow the whole capsule. Bedtime administration may be a potential method for managing nausea. If you miss or vomit a dose take the next dose at its regular scheduled time. Do not take an additional dose.
Storage: Store at 20-25°C (68-77°F); excursions are permitted between 15-30°C (59-86°F). 
Niraparib in Prostate Cancer Treatment:
Niraparib, a drug not yet approved by the FDA, is being studied in clinical trials for treating prostate cancer that has progressed after hormone therapy, with a median progression-free survival of 13.6 months, and is also being tested for resistant prostate cancer. 
Niraparib and Abireterone Acetate/ Niraparib Akeega:
Prostate cancer can be treated with two drugs: niraparib and abiraterone acetate (AAP). Niraparib is a PARP inhibitor that blocks the activity of PARP, a protein that helps cells repair damaged DNA. Cancer cells rely on PARP to repair their DNA, so blocking it can lead to cancer cell death. AAP, on the other hand, is an androgen receptor (AR) inhibitor that blocks the production of testosterone, a hormone essential for prostate cancer growth. 
Niraparib FDA Approval:
Niraparib has been approved by the US Food and Drug Administration (FDA) for the following indications:
- Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy This approval was granted on April 29, 2020.
- Treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has progressed after three or more prior chemotherapy treatments in patients with a BRCA mutation (a mutation in the BRCA1 or BRCA2 gene) This approval was granted on March 27, 2017.
- Treatment of adult patients with advanced high-grade serous epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer in patients with homologous recombination deficiency (HRD), regardless of BRCA mutation status This approval was granted on November 29, 2022. 
Niraparib Success Rate:
Clinical trials are being conducted to study the combination of Niraparib and AAP as a treatment for prostate cancer. In a phase 3 clinical trial, the combination of these drugs was found to be effective in improving progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without alterations in homologous recombination repair (HRR) genes. The results showed that patients who received the combination had a median PFS of 24.8 months, while those who received AAP alone had a median PFS of 14.8 months. 
Read more about PARP inhibitors and Recurrence Ovarian Cancer
How to order Niranib-100mg-Niraparib-Zejula ?
Ordering any medicine from our website is very easy. We attach our contact info with the product image, anyone can reach us by that contact info. Or you may go to our contact us page and then send us a text referring to your query like which medicine you want to purchase, how many quantities of the product you want, which shipping method you would prefer, etc. Simply tell us the medicine name, medicine quantity, where to send I mean the country name, your mailing address. For any kind of query, you may mail us, or send a text message through WhatsApp, or WeChat at +8801304498958.
What is Niranib 100mg (Niraparib) - Zejula?
Niranib 100mg, also known by its generic name Niraparib, is a medication marketed under the brand name Zejula. It belongs to a class of drugs called PARP inhibitors and is primarily used for the treatment of certain types of cancer.
How does Niranib 100mg work?
Niranib 100mg (Niraparib) works as a PARP inhibitor, which means it blocks an enzyme called poly ADP-ribose polymerase (PARP). By inhibiting PARP, the drug prevents cancer cells from repairing their damaged DNA, ultimately leading to their death.
What types of cancer does Niranib 100mg (Niraparib) treat?
Niranib 100mg is approved for the treatment of ovarian cancer. It is used in specific cases, such as advanced ovarian cancer with germline or somatic BRCA mutations, as well as in patients who have had a complete or partial response to platinum-based chemotherapy.
How is Niranib 100mg (Niraparib) administered?
Niranib 100mg (Niraparib) comes in the form of oral capsules. The usual recommended dose is typically taken once daily, with or without food, as directed by your healthcare provider.
What are the common side effects of Niranib 100mg (Niraparib)?
Like any medication, Niranib 100mg may cause side effects. Some common side effects include nausea, fatigue, constipation, headache, and low blood cell counts. It is essential to discuss any concerning side effects with your doctor.
Can Niranib 100mg (Niraparib) be used during pregnancy?
Niranib 100mg (Niraparib) may harm an unborn baby, and its use during pregnancy is generally not recommended. If you are pregnant or planning to become pregnant, you must inform your healthcare provider before starting this medication.
Can I take other medications while on Niranib 100mg (Niraparib)?
It is crucial to inform your doctor about all the medications you are currently taking, including prescription drugs, over-the-counter medicines, and any herbal supplements. Some medications may interact with Niranib 100mg, potentially affecting its effectiveness or causing adverse effects.
Is Niranib 100mg (Niraparib) suitable for everyone with ovarian cancer?
Niranib 100mg (Niraparib) is not suitable for all patients with ovarian cancer. It is specifically prescribed for those who have specific genetic mutations or those who have had a response to previous treatments. Your doctor will determine if Niranib 100mg is the right treatment for your condition.
How long will I need to take Niranib 100mg (Niraparib)?
The duration of Niranib 100mg treatment will depend on your response to the medication and the recommendation of your oncologist. It may be used for an extended period if it continues to be effective in managing your condition.
Is it safe to drive or operate heavy machinery while on Niranib 100mg (Niraparib)?
Niranib 100mg may cause dizziness or fatigue in some patients. If you experience such side effects, avoid driving or operating heavy machinery until you feel alert and capable of performing these tasks safely.
Can I consume alcohol while taking Niranib 100mg (Niraparib)?
It is generally advisable to avoid alcohol consumption while taking Niranib 100mg, as alcohol may interact with the medication and lead to increased side effects or reduced effectiveness.
What should I do if I miss a dose of Niranib 100mg (Niraparib)?
If you miss a dose of Niranib 100mg, take it as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one.